Apixaban vs vitamin K antagonist and aspirin vs placebo in atrial fibrillation with acute coronary syndrome or PCI

Phase 4, randomised, single-blind trial of apixaban and aspirin in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and coronary arteriosclerosis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Major or clinically relevant non-major bleeding comparing apixaban vs vitamin K antagonist and Major or clinically relevant non-major bleeding comparing no aspirin vs aspirin. Started Jun 2016; status: active, not recruiting.